In our study, we proposed a comprehensive machine learning approach and feature selection assessment to efficiently detect EGFR and KRAS mutations in patients with NSCLC; early detection of these mutations can help in the administration of suitable individualized and targeted treatment options. Here, KRAS is linked to non-small cell lung carcinoma.